Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 214,396 shares of the company's stock after selling 29,456 shares during the quarter. New York State Common Retirement Fund owned 0.22% of Neurocrine Biosciences worth $28,249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in NBIX. Assenagon Asset Management S.A. increased its stake in Neurocrine Biosciences by 120.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company's stock worth $65,761,000 after acquiring an additional 319,564 shares during the last quarter. Westfield Capital Management Co. LP increased its position in shares of Neurocrine Biosciences by 73.0% during the 3rd quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company's stock valued at $73,045,000 after purchasing an additional 273,952 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Neurocrine Biosciences by 59.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company's stock valued at $77,892,000 after purchasing an additional 256,920 shares during the last quarter. Jennison Associates LLC increased its position in shares of Neurocrine Biosciences by 86.0% during the 3rd quarter. Jennison Associates LLC now owns 409,475 shares of the company's stock valued at $46,066,000 after purchasing an additional 189,345 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Neurocrine Biosciences by 81.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 410,103 shares of the company's stock valued at $54,035,000 after purchasing an additional 184,660 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NBIX shares. Wells Fargo & Company raised Neurocrine Biosciences from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $140.00 to $170.00 in a research report on Wednesday. StockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 8th. HC Wainwright reissued a "buy" rating and set a $150.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday. The Goldman Sachs Group upped their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a "buy" rating in a research report on Thursday, January 25th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a research report on Tuesday. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $142.38.

Insider Activity

In other news, CEO Kevin Charles Gorman sold 2,707 shares of the stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total value of $380,847.83. Following the transaction, the chief executive officer now directly owns 502,188 shares of the company's stock, valued at $70,652,829.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Eric Benevich sold 75,000 shares of the firm's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the sale, the insider now directly owns 40,778 shares of the company's stock, valued at $5,683,637.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin Charles Gorman sold 2,707 shares of the firm's stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total value of $380,847.83. Following the sale, the chief executive officer now directly owns 502,188 shares in the company, valued at $70,652,829.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 186,994 shares of company stock valued at $25,806,409. Company insiders own 4.40% of the company's stock.

Neurocrine Biosciences Trading Down 1.3 %

Shares of NBIX stock traded down $1.77 during mid-day trading on Friday, reaching $135.99. The stock had a trading volume of 717,575 shares, compared to its average volume of 847,914. The business's fifty day moving average is $136.63 and its 200-day moving average is $127.85. The firm has a market cap of $13.53 billion, a price-to-earnings ratio of 56.19 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 1-year low of $89.04 and a 1-year high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating analysts' consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company's revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.88 earnings per share. On average, analysts forecast that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.